CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 15, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Capricor touted its successful movement towards FDA approval for its deramiocel drug candidate, such as a mid-cycle review with no important deficiencies and the planning of an advisory committee meeting. Despite this positivity, the Company was concealing adverse data from the Phase 2 HOPE-2 trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Wolfe Research Sticks to Its Buy Rating for Sotera Health (SHC)
In a report released today, Michael Polark from Wolfe Research maintained a Buy rating on Sotera Health, with a price target of $17.00. The company's shares closed today at $13.97. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Polark is a 4-star analyst with an average return of 6.5% and a 50.31% success rate. Polark covers the Healthcare sector, focusing on stocks such as Insulet, Medtronic, and Steris. In addition to Wolfe Research, Sotera Health also received a Buy from Barclays's Luke Sergott in a report issued today. However, on August 1, TR | OpenAI – 4o reiterated a Hold rating on Sotera Health (NASDAQ: SHC). Based on Sotera Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $254.52 million and a GAAP net loss of $13.26 million. In comparison, last year the company earned a revenue of $248.18 million and had a net profit of $6.32 million
Business Insider
2 hours ago
- Business Insider
Citi Sticks to Their Buy Rating for Zai Lab (ZLAB)
In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on Zai Lab, with a price target of $69.00. The company's shares closed today at $34.96. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Sarepta Therapeutics, and Zai Lab. According to TipRanks, Nochomovitz has an average return of 5.2% and a 40.00% success rate on recommended stocks. In addition to Citi, Zai Lab also received a Buy from Jefferies's Michael Yee in a report issued on July 24. However, today, Bank of America Securities reiterated a Hold rating on Zai Lab (NASDAQ: ZLAB). ZLAB market cap is currently $4.38B and has a P/E ratio of -13.66. Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZLAB in relation to earlier this year. Most recently, in May 2025, Scott W Morrison, a Director at ZLAB sold 23,799.00 shares for a total of $714,921.96.
Yahoo
2 hours ago
- Yahoo
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy now. On July 29, Bausch Health Companies announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX). The acquisition is valued at ~$63 million upfront with potential for an additional $350 million in sales milestone payments, and will be an all-cash transaction. Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an epigenetic modulator that the FDA has granted Breakthrough Therapy Designation for the treatment of alcoholic hepatitis/AH, which is a life-threatening form of alcohol-associated liver disease. A closeup of pills in a pharmacy, representing the high quality medications of the company. AH is characterized by severe liver inflammation & necrosis and accounted for ~164,000 hospital admissions in the US in 2021. There are currently no FDA or European Medicines Agency/EMA-approved treatments for the condition. The acquisition of larsucosterol strengthens Bausch Health's commitment to hepatology. Bausch Health plans to use its expertise to advance larsucosterol through a planned Phase 3 program. Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health. DURECT Corporation (NASDAQ:DRRX) is a late-stage biopharmaceutical company that develops epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, such as acute organ injury. While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
